Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Schedule of ResponseDX Accounts Receivable

ResponseDX^® accounts receivable consisted of the following:

	December 31,		December 31,
	2012		2013
Net Medicare receivable	$	890,936	$	2,422,611
Net Private Payor receivable		2,924,412		4,315,587
		3,815,348		6,738,198
Allowance for doubtful accounts		(991,990)		(2,404,659)
	$	2,823,358	$	4,333,539

Schedule of Estimated Useful Lives of Property and Equipment

The Company has determined the estimated useful lives of its property and equipment, as follows:

Laboratory equipment	5 to 7 years
Furniture and equipment	5 to 7 years
Purchased and internally-developed software	3 to 5 years
Leasehold improvements	Shorter of the useful life (5 to 7 years) or the lease term

Schedule of ResponseDX Revenue

The following details ResponseDX^® revenue for the years ended December 31, 2012 and 2013:

	Year Ended December 31,
	2012		2013
Net Medicare revenue	$	5,405,393	$	4,521,732
Net Private Payor revenue		6,472,386		7,489,642
Other		6,354		—
Net ResponseDX® revenue	$	11,884,133	$	12,011,374

Schedule of Revenue Sources that Account for Greater than 10 Percent of Total Revenue

Revenue sources that accounted for greater than 10 percent of revenue are provided below.

	Year Ended December 31,
	2012					2013
	Revenue		Percent of Total Revenue			Revenue		Percent of Total Revenue
GlaxoSmithKline entities:
GlaxoSmithKline LLC	$	1,280,704		6.8	%	$	1,134,366		5.8	%
GlaxoSmithKline Biologicals S.A.	$	3,241,211		17.3	%	$	3,534,619		17.9	%
Total GlaxoSmithKline entities	$	4,521,915		24.1	%	$	4,668,985		23.7	%
Medicare, net of contractual allowances	$	5,405,393		28.8	%	$	4,521,732		22.8	%

Schedule of Customers that Account for Greater than 10 Percent of Accounts Receivable

Clients that accounted for greater than 10 percent of accounts receivable are provided below.

	As of December 31,
	2012					2013
	Receivable Balance		Percent of Total Receivables			Receivable Balance		Percent of Total Receivables
GlaxoSmithKline entities:
GlaxoSmithKline LLC	$	200,169		3.1	%	$	597,937		6.9	%
GlaxoSmithKline Biologicals S.A.	$	1,490,975		23.4	%	$	544,298		6.3	%
Total GlaxoSmithKline entities	$	1,691,144		26.5	%	$	1,142,235		13.2	%
Medicare, net of contractual allowances	$	890,936		14.0	%	$	2,422,611		28.1	%